Waystar Considers Sale Amid Market Challenges, Sources Reveal

Waystar, a prominent healthcare software provider, is reportedly exploring strategic alternatives, including a potential sale. The company, which went public two years ago, has seen its market value decrease to approximately $4.8 billion after a 24% decline in its share price this year. This development comes amid a broader downturn in the software sector, according to seven individuals familiar with the matter.

The Lehi, Utah, and Louisville, Kentucky-based company has engaged investment bank Evercore to guide the exploratory process, which remains in its initial stages. Two sources, who requested anonymity due to the confidentiality of the discussions, indicated that the outcome is uncertain, and a sale may not occur.

Market Position and Valuation Challenges

Waystar has positioned itself as a technology-driven firm, focusing on automating and managing administrative functions for healthcare providers. This strategy aimed to capitalize on the higher valuations typically associated with tech companies, as opposed to businesses reliant on manual services. Initially, investors were enthusiastic, propelling the stock from $20 to a peak of $45 in 2025. However, concerns over potential disruptions from advancements in artificial intelligence have since put pressure on the stock, as noted by Morgan Stanley analysts in a July report.

The company emerged from a 2017 merger between Zirmed and Navicure, both healthcare revenue management firms. Its major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who took the company public in 2024. EQT remains the largest shareholder with a 13% stake, while CPPIB holds 10%, and BlackRock Institutional Trust Company owns 8%, according to data from LSEG.

Stakeholder Reactions and Potential Outcomes

As Waystar evaluates its options, the broader investment community is watching closely to assess whether interest in software companies is rebounding. Neither Waystar nor Evercore has offered comments on the ongoing proceedings. Similarly, EQT and BlackRock declined to comment, while CPPIB has yet to respond to inquiries.

This situation underscores the volatility and challenges faced by software firms in the current market environment, particularly those in the healthcare sector. As Waystar moves forward, the decisions made could significantly impact its trajectory and the perceptions of investors regarding the potential of healthcare technology companies.